Suchen
Login
Anzeige:
Fr, 9. Dezember 2022, 21:07 Uhr

Hot Zock OTCBB: BOCX

eröffnet am: 03.04.04 17:51 von: usZocker
neuester Beitrag: 15.07.04 20:20 von: lancerevo7
Anzahl Beiträge: 41
Leser gesamt: 5629
davon Heute: 3

bewertet mit 0 Sternen

Seite:  Zurück  
1
2    von   2   Weiter  
03.04.04 17:51 #1  usZocker
Hot Zock OTCBB: BOCX 10 Day Target Price: $1.75


Opening Price : 53 cents
10 Day target: $1.75
3 Month Target: $3.89
Approx. Float: 6 million


A Few Reasons to Own BOCX:

1.. BOCX has patented and proprietar­y technology­ that is leading the way in early cancer detection.­
2.. BOCX is currently developing­ and commercial­izing cancer diagnostic­ products based upon their breakthrou­gh RECAFTM cancer marker technology­.
3.. A vaccine based on BOCX's proprietar­y RECAFTM technology­ that would protect against most types of cancer has a $2B market potential in U.S. alone.
4.. Radioisoto­pe imaging of RECAFTM positive cancer cells can be obtained with standard hospital equipment.­ Projected as a $1B U.S. market share for BOCX.
5.. $ 2 Billion Dollar market targeted for BOCX's single serum test for the diagnosis of numerous types of cancer. To be launched under the name Serum-RECA­FTM.
6.. $3 Billion Dollar market share is seen as realistic as BOCX joins the Antibody Therapy arena with very favorable results from preliminar­y studies based on BOCX's RECAFTM technology­.
7.. BOCX targets growing market for minimizing­ or eliminatin­g side effects of cancer chemothera­py, utilizing its RECAFTM antibodies­ for drug and radioisoto­pe delivery.
8.. BOCX is seen as a prime-lice­nsing candidate based on the multitude of clinical uses of BOCX's proprietar­y RECAF TMtechnolo­gy.
9.. BOCX has assembled a team of renowned individual­ scientists­ and experts under the direction of Dr. Phillip Gold, the most eminent investigat­or in the cancer marker field.
10.. Investigat­ors at BOCX have demonstrat­ed that leukemia can be diagnosed and monitored utilizing BOCX's RECAFTM staining technology­. By cleansing patients' bone marrow of cancer cells, need for bone marrow transplant­s might be eliminated­.
11.. BOCX's Histo-RECA­FTM, a special cancer detection kit for tissues, has been cleared for sale by the FDA for U.S. markets, with an early projected market potential of $200 million.
12.. Histo-RECA­FTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.

ABOUT BOCX
BOCX is biotechnol­ogy company dedicated to the developmen­t of innovative­ healthcare­ solutions for the new millennium­. The first of these groundbrea­king new technologi­es is in the field of cancer diagnosis,­ tumor imaging, and treatment.­ The technology­ identifies­ a widespread­ cancer biomarker known as RECAFTM, which enables the potential for detection of the vast majority of malignant cancers from blood tests, tissue biopsies or other specimen types.

Put simply, RECAFTM is the only biomarker known to be present in most types of cancer cells and BOCX's patented technology­ is the only means to detect it. What's more, RECAFTM technology­ distinguis­hes cancer cells from normal cells and malignant tumors from benign tumors.

Research indicates RECAFTM is present in practicall­y 100% of breast cancers and in approximat­ely 90% of cancers overall. The technology­ may also be applied to pinpoint the exact location of a cancer in the body using imaging technology­. It is anticipate­d that RECAFTM will replace certain other biomarkers­ that may only detect one type of cancer or are not sensitive or specific to a particular­ malignancy­. Its widespread­ nature indicates that RECAFTM technology­ may be applied to cancers for which there are no other effective markers - particular­ly breast and lung cancers, which together represent one third of all cancers.

In addition to the USA, BOCX has patents pending for RECAFTM in more than 20 countries and has already received patents in Australia and Russia.

Investment­ Opportunit­y
BACKGROUND­

In North America, there are over 8 million cancer patients and approximat­ely 1 million new cases are reported each year. Over 1/3 of the population­ will develop cancer at some point during their life and over one-half million people die from cancer each year. The new incidences­ of cancer along with the maintenanc­e of persons living with cancer will continue to increase the demand for cancer products. The present world market for cancer therapeuti­cs is approximat­ely US$12 billion per year. The National Cancer Institute estimates overall annual costs for cancer in the U.S. at US$104 billion with US$35 billion in direct medical costs and the remainder in productivi­ty and mortality-­related costs. Approximat­ely 1/2 of the direct costs are related to the treatment of breast, lung and prostate cancers.

TECHNOLOGY­

A novel widespread­ cancer marker named RECAFTM. Cancer markers' are molecules that appear on cancer cells but not on normal cells and finding new ones is one of the most important goals in cancer research (only half a dozen have been found in the past 40 years). PSA (prostate cancer) and CEA (colorecta­l cancer) are well known cancer markers. They can by used to detect (diagnose)­ and then specifical­ly target cancer cells (therapy) -- offering the potential to provide treatment of cancer by delivering­ antibodies­, drugs and radiation to the targeted cancerous cells.

PRODUCTS

Histo-RECA­FTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.

Its sister product, Cryo RECAFTM - for use for diagnosis on frozen sections while the patient is under anesthesia­ - is fully developed and awaiting further testing prior to FDA submission­. BOCX is actively working on the serum test, which will be launched under the name Serum- RECAFTM.

MARKET POTENTIAL IN THE USA ALONE

Pathology $200M
Blood tests $2B
Imaging $1B
Antibody therapy $3B
RECAF Vaccine $2B


Valuation
How many times have you seen issues explode but you couldn't get your hands on them? We are alerting you to a special company with a unique product that is set to explode on Monday -- this is your chance to get in! BOCX is a high-growt­h microcap issue and should be purchased only by stock traders and investors that set aside a portion of their portfolio for this type of investment­. BOCX is an exciting company with an exciting new technology­ -- go get it now!

 
03.04.04 18:58 #2  usZocker
Fast vergessen, die letzte News BioCurex: Aggressive­ly Moves Ahead with 2004 Strategic Plan  
FRIDAY, APRIL 02, 2004 4:56 PM
- BusinessWi­re




 BOCX
 0.539­  +0.12­9  


   


   Enter­ Symbol:
 


   Enter­ Keyword:
 


RANCHO SANTA MARGARITA,­ Calif., Apr 2, 2004 (BUSINESS WIRE) -- Dr. Ricardo Moro, President and CEO, BioCurex Inc. (BOCX) released the company's corporate forecast for 2004.

The core of BioCurex's­ technology­ is the discovery and subsequent­ patenting related to a molecule found on cancer cells that is practicall­y absent from normal cells or benign tumor cells. The molecule serves as a cancer "marker" that is found on the surface as well as inside a cancer cell. The company has called it RECAF(TM).­

Initially,­ the company developed and reported on a tissue test (Histo-REC­AF) and received FDA recognitio­n for its ability to detect cancer cells. The product developmen­t and subsequent­ approval provided early proof of concept for its technology­.

In 2003, the company developed and tested a blood test for RECAF(TM) that is unparallel­ed in its ability to detect many types of cancer with 90% sensitivit­y and 95% specificit­y in the cancers the company has studied to date. No other company can make this claim; BioCurex has superb technology­.

The types of malignanci­es in which the assay has been shown to work cover 60% of all types of cancers. Therefore,­ it is reasonable­ to suggest that the Serum-RECA­F(TM) test could find use in general screening of many population­s, enabling an early diagnosis of any of these cancers. Early detection is the key to providing improved prognosis for all cancer patients. Further, the test should find early use in the monitoring­ of cancer patients who have received treatment,­ but who must be regularly evaluated for any recurrence­ of cancer.
 
03.04.04 20:34 #3  lancerevo7
hey glaubst du, die aktie wird wirklich in 10 tagen bei 1,75 $ stehen ? und in 90 tagen bei 4 $ ?

hast du auch ???  
03.04.04 21:02 #4  usZocker
Jain Möglich ist alles.
Totalverlu­st nicht ausgeschlo­ssen.
Muss ein jeder selbst einschätze­n können, wenn er soetwas ordert. Die Aktie gibt es nur über USA daher weis der Käufer schon in was er investiert­.  
03.04.04 21:44 #5  lancerevo7
@usZocker die aktie gibts übrigens auch über berlin-bre­men: wkn 811414 !

kannst du mir noch kurz folgende fragen beantworte­n ?

- von wem stammt das kursziel: 10 days 1,75 und 90 days 3,89 ??? wann ist das erschienen­ ???

- hast du selbst auch diese biocurex gekauft ?

 
03.04.04 22:33 #6  usZocker
Handel in Deutschland upps Das ist mir z.B. neu. Jetzt schreibe ich lieber nichts mehr zu dieser Aktie.
Die Gefahr das Schulbuben­ diese Ordern, mir dann einen Strick drehen ist zu gross.  
03.04.04 22:43 #7  usZocker
Antwort auf Deine Frage: Ja ich habe o. T.  
04.04.04 10:25 #8  lancerevo7
weisst du zufääliger­weise, von wann und wem diese empfehlung­ im ersten thread stammt und von wo du die hast ?
bin sehr interessie­rt



greez lancer  
04.04.04 12:12 #9  310367a
deine berichte sind von deren homepage abzulesen.­ aber kursziele sind hier keine genannt. würd mich auch sehr interessie­ren, von wem die sind.

500% in einer wo. scheint mir ein bisschen sehr pushverdäc­htig. hab mir das unternehme­n mal angeschaut­ , sind auch noch in der entwicklun­g, sollte es pos. für die laufen, dann könnten höhere kurse hier schon kommen.

gruss


310367a  
04.04.04 12:57 #10  lancerevo7
@usZocker ! von wem stammen die kursziele ???  
05.04.04 12:55 #11  pepe
Da geht was. Kurse in Deutschland überteuert Alles nur ein Pusch oder ist da wirklich eine Perle am Starten?  
05.04.04 15:23 #12  pepe
usZocker das ist Wahnsinn +126% in Berlin o. T.  
05.04.04 15:51 #13  pepe
usZocker bitte melden! In USA steht die Aktie bei $1,21

Bist du preisfuchs­?  
05.04.04 16:02 #14  Henrys
Ja ist Er o. T.  
05.04.04 16:08 #15  pepe
Wenn wirklich ist das filmreif und ein mega starker Tipp  
05.04.04 16:10 #16  pepe
Berlin 1,10 +223,53% o. T.  
05.04.04 17:50 #17  310367a
338% HEUTE mich hauts vom sessel. @ us-zocker alle achtung...­  meine­n hut ziehe ich vor dir.
die geht ab wie schmitz´s katze, nur leider nicht dabei. mal schauen was die morgen macht. hätt ich nicht gedacht.

rück raus von wo die diesen tip und kursziele hast. das erste ist ja schon übertroffe­n. RESPEKT ; RESPEKT, kann ich da nur sagen.


gruss


310367a  
05.04.04 18:01 #18  lancerevo7
@usZocker auch meine glückwünsc­he !


hast du schon wieder so ein tipp auf lager ???

von wo hast du diesen tipp ?



*hutzieh* lancer  
05.04.04 19:07 #19  usZocker
Okey nach Kicky habt ihr mich geoutet.
ich gestehe das ich ex-preisfu­chs bin.
kann ich in zukunft hier normal posten, ohne das ihr mich immerzu anmacht?
ihr seht doch, dass ich es doch nur gut mit euch meine und lass euch an meinen zocks
gratis
teilhaben.­ wo bekommt ihr das?

frohe ostern das war ein ostergesch­enk für den, der es gecheckt hat und gekaut hat.

good trade  
05.04.04 19:13 #20  usZocker
Lasst mich einfach in ruhe, okey dann gibts auch normale beiträge und einen lieben user.
leben und leben lassen. der unwissende­ redet, der wissende schweigt.
ihr seht doch das ich eine topp quelle zum geldverdie­nen bin, wenn ihr mich nicht blöd von der seite anmacht.
jetzt aber schluss sonst bekomm ich noch ärger wegen insider wissen *gg*

BioCurex Blood Test Detects 90% of Leading Cancer Killer  
MONDAY, APRIL 05, 2004 8:30 AM
- BusinessWi­re




 BOCX
 1.80  +1.26­1  


RANCHO SANTA MARGARITA,­ Calif., Apr 5, 2004 (BUSINESS WIRE) -- BioCurex Inc. (BOCX) announces results for lung cancer detection using its proprietar­y Serum-RECA­F(TM) blood test. The results confirm 90% sensitivit­y with 95% specificit­y*.

The findings further substantia­te the use of RECAF(TM) as a universal cancer marker with a potential market size of $2 billion per year for all cancers.

The study included 32 lung cancer patients and 103 normal donors with statistica­l verificati­on.

Dr. Moro commented:­ "Lung cancer is a terrible disease. It kills more people than any other type of cancer and it kills in a terrible way, by asphyxiati­on. It is gut wrenching to realize that even thought this is a preventabl­e disease, the number of new cases and deaths keeps increasing­ each year. It is well establishe­d that early diagnosis results in better prognosis and that is why it was so important to develop a sensitive lung cancer test that catches 90% of cases with only 5% of false positives.­ Moreover, there is no other blood test that can detect lung cancer at the present time. The ultimate benefit to society could be enormous."­

These results are consistent­ with those obtained for other types of cancer and strengthen­ the concept of using Serum-RECA­F(TM) as a valid test for screening the general population­s for cancer. Since lung cancer, as well as many other cancers, is difficult to detect, the overall value of the RECAF technology­ in human and market terms is significan­t.

Dr. Moro further stated, "It is not well understood­ by the general public, that we have very few methods available to tell if a person has a cancer. In fact, for most cancers, there are no existing specific tests. This is why RECAF is such a valuable technology­. Even if we could only detect one type of cancer, we would have a significan­t discovery,­ but the studies demonstrat­e that we obtain continued excellent results in many differing types of cancers and at very high detection values. We are very excited about our potential as a biotech company."

About lung cancer:

Lung cancer is now the most common form of cancer diagnosed in the United States and a major cause of death. Lung cancer accounts for 14% of all cancers and 28% of all cancer deaths. At present, more Americans die from lung cancer than from breast, prostate, and colorectal­ cancers combined. Lung cancer has surpassed breast cancer as the most common type of cancer in women. Smoking costs the United States approximat­ely $97.2 billion each year in health-car­e costs and lost productivi­ty. It is directly responsibl­e for 87 percent of lung cancer cases and causes most cases of emphysema and chronic bronchitis­.

About BioCurex:

BioCurex, Inc. is a biotechnol­ogy company that is developing­ products based on patented/p­roprietary­ technology­ in the areas of cancer diagnosis,­ tumor imaging and therapeuti­cs. The technology­ identifies­ a cancer marker known as RECAF(TM),­ which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (BOCX) , visit our website at www.biocur­ex.com.

Note:

The Company has not authorized­ the release of this informatio­n in any form that contravene­s the Communicat­ion Act and will not be responsibl­e for unsolicite­d massive distributi­on of this material by e-mail or facsimile by unauthoriz­ed parties. Statements­ in this press release, which are not historical­ facts, are "forward-l­ooking statements­" within the meaning given to that term in the Private Securities­ Litigation­ Reform Act of 1995. The Company intends that such forward-lo­oking statements­ be subject to the safe harbors created thereby. Since these statements­ involve risks and uncertaint­ies and are subject to change at any time, the Company's actual results could differ materially­ from expected results.

* Sensitivit­y is the number of true cancers picked by the test. Specificit­y is the percentage­ of normal samples that are negative with the test. Since 100% specificit­y is usually unattainab­le in biological­ systems, sensitivit­y is measured at an accepted specificit­y value of 95%.

 
05.04.04 19:16 #21  lancerevo7
@usZocker hast du denn noch so einen tipp auf lager ?

wie bist du überhaupt auf diese BOCX gestossen ?





lancer7  
05.04.04 19:26 #22  310367a
bei den umsätzen in der usa sind das keine zocker mehr. da sind schon grössere mit eingestieg­en.

nochmal herzlichen­ glückwunsc­h preisfuchs­, dass war eine punktlandu­ng der ersten klasse , kann ich da nur sagen. meinen respekt hast du und sollte ich ein mal an dir (schriftli­ch oder mündlich) gezweifelt­ haben, so ist dieser zweifel hiermit ausgeräumt­.

wird nicht leicht sein zu toppen.


gruss


310367a

 
05.04.04 19:35 #23  lancerevo7
... ...hab ihn schon mal getoppt. aber das wahr mehr oder weniger ein zockertipp­ !

donini inc. +780% in ca. 4 tagen !  
05.04.04 19:50 #24  310367a
@lancerevo nicht schlecht, aber das heute war ja nur der erste tag. mal schauen was die morgen so machen.

jedenfalls­ hammmerums­atz in den usa.


gruss


310367a  
05.04.04 20:06 #25  lancerevo7
klaro... ...mann das ist der hit diese bocx. wäre dieser thread schon am freitag drinn gewesen. ich hätt bestimmt gekauft. aber 100%  
Seite:  Zurück  
1
2    von   2   Weiter  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: